$16.23
5.05% today
Nasdaq, Oct 15, 06:19 pm CET
ISIN
US26817R1086
Symbol
DYN

Dyne Therapeutics Inc Stock price

$15.45
+2.59 20.14% 1M
+7.98 106.83% 6M
-8.11 34.42% YTD
-17.86 53.62% 1Y
+2.26 17.13% 3Y
-2.23 12.61% 5Y
-8.45 35.36% 10Y
-8.45 35.36% 20Y
Nasdaq, Closing price Tue, Oct 14 2025
+1.42 10.12%
ISIN
US26817R1086
Symbol
DYN
Industry

Key metrics

Basic
Market capitalization
$2.2b
Enterprise Value
$1.6b
Net debt
positive
Cash
$683.9m
Shares outstanding
114.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.9
Financial Health
Equity Ratio
91.1%
Return on Equity
-50.4%
ROCE
-64.1%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-439.0m | $-445.6m
EBIT
$-440.9m | $-480.5m
Net Income
$-412.9m | $-423.3m
Free Cash Flow
$-361.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-62.9% | -30.2%
EBIT
-62.7% | -39.7%
Net Income
-60.3% | -33.4%
Free Cash Flow
-64.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.6
FCF per Share
$-3.2
Short interest
14.0%
Employees
206
Rev per Employee
$0.0
Show more

Is Dyne Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Dyne Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Dyne Therapeutics Inc forecast:

17x Buy
85%
3x Hold
15%

Analyst Opinions

20 Analysts have issued a Dyne Therapeutics Inc forecast:

Buy
85%
Hold
15%

Financial data from Dyne Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 61 61
21% 21%
-
- Research and Development Expense 380 380
72% 72%
-
-439 -439
63% 63%
-
- Depreciation and Amortization 1.89 1.89
17% 17%
-
EBIT (Operating Income) EBIT -441 -441
63% 63%
-
Net Profit -413 -413
60% 60%
-

In millions USD.

Don't miss a Thing! We will send you all news about Dyne Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dyne Therapeutics Inc Stock News

Positive
Seeking Alpha
7 days ago
Dyne Therapeutics received positive FDA feedback enabling a registrational cohort for z-basivarsen in DM1, with Accelerated Approval possible using vHOT as intermediate efficacy endpoint. DYN expects key catalysts: DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late 2026. The pipeline includes zeleciment rostudirsen for DMD e...
Neutral
GlobeNewsWire
9 days ago
- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall disease burden reported by both patients and physicians - WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc.
Neutral
GlobeNewsWire
13 days ago
WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company.
More Dyne Therapeutics Inc News

Company Profile

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Head office United States
CEO John Cox
Employees 206
Founded 2017
Website dyne-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today